Potential clinical applications of OXPHOS inhibitors
| Cancer | Subtype | Associated gene expression | Ref. |
|---|---|---|---|
| Acute myelogenous leukemia (AML) | AML stem cells | ↑BCL-2 | (27) |
| Chronic lymphocytic leukemia (CLL) | Src-sensitive CLL after Src inhibition | ↓AKT | (74) |
| Classical Hodgkin lymphoma | ↑NF-κB | (25) | |
| Diffuse large B-cell lymphoma | High OXPHOS expression | (26) | |
| Breast | ↓RB1 | (22, 24) | |
| Pancreatic ductal adenocarcinoma (PDAC) | PDAC (stem-like) cells | ↑Ras | (29) |
| Lung adenocarcinoma | (18) | ||
| NSCLC | NSCLC after EGFR inhibition | ↓EGFR | (75) |
| NSCLC | Oncogenic Kras and loss of LKB1 | ↓LKB1, oncogenic Kras | (35) |
| Endometrial carcinoma | Serous-like endometrial | mtDNA copy number alteration | (18) |
| Melanoma | High OXPHOS expression | ↑ PPARGC1A (PGC1α) | (34) |
| Melanoma | BRAF mutant after BRAF inhibition | ↑ PPARGC1A (PGC1α), BRAF activating mutation | (32, 33) |
| Glioma | Low-grade glioma | IDH1 activating mutation | (18) |
| Head and neck, cervix, lung, brain, bowel, prostate, pancreas | Hypoxic solid tumors | (36) |